The Food and Drug Administration (FDA) issued a new alert in which it has said that Fluvoxamine, an antidepressant drug, is not approved for the treatment of COVID-19. It said the drug is only approved for obsessive-compulsive disorder (OCD), depression, anxiety, and other mood disorders.

The post FDA Doesn’t Issue Approval of Fluvoxamine for COVID-19 Infection appeared first on Latest Health & Medical News – Myhealthyclick.com.